Gastrointestinal (GI) and Microbiome Explorers: Development of Swallowable Smart Pills or Devices for Precision Nutrition, Microbiome and Digestive Disease Applications (R21/R33 Clinical Trial Required)
Funding Opportunity PAR-20-133 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to support the development of tools/devices for sampling or monitoring of diet- GI (contents and mucosa) and microbial interactions (GI- Microbiome Explorer). It is anticipated that successful completion of the projects completed under this FOA will yield implementable devices/tools for gastroenterological research or other clinical applications, along with monitoring and sampling of GI contents and/or mucosa to examine diet-host-microbiome interactions for clinical research or diagnostic a...
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 11, 2020 Category: Research Source Type: funding
Gastrointestinal (GI) and Microbiome Explorers: Development of Swallowable Smart Pills or Devices for Precision Nutrition, Microbiome and Digestive Disease Applications (R21/R33 Clinical Trial Required)
The purpose of this Funding Opportunity Announcement is to support the development of tools/devices for sampling or monitoring of diet- GI (contents and mucosa) and microbial interactions (GI- Microbiome Explorer). It is anticipated that successful completion of the projects completed under this FOA will yield implementable devices/tools for gastroenterological research or other clinical applications, along with monitoring and sampling of GI contents and/or mucosa to examine diet-host-microbiome interactions for clinical research or diagnostic applications.Lan Tian | PAR-20-133 (Source: NIDDK Funding Opportunities)
Source: NIDDK Funding Opportunities - March 11, 2020 Category: Endocrinology Source Type: funding
Notice of Special Interest: Development of Swallowable Smart Pills or Devices for Precision Nutrition, Microbiome and Digestive Disease Applications
The purpose of this Notice is to inform potential applicants of an area of special interest in developing swallowable smart pills or devices to advance precision nutrition, microbiome and gastroenterological research.Christopher J. Lynch, Ph.D. | NOT-DK-20-001 (Source: NIDDK Funding Opportunities)
Source: NIDDK Funding Opportunities - November 1, 2019 Category: Endocrinology Source Type: funding
Request for Information (RFI): Swallowable Smart Pills or Devices to Enable Precision Nutrition, Microbiome and Gastroenterological Research
Notice NOT-DK-19-020 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 25, 2019 Category: Research Source Type: funding
Request for Information (RFI): Swallowable Smart Pills or Devices to Enable Precision Nutrition, Microbiome and Gastroenterological Research
The purpose of this Request for Information (RFI) is to solicit public input to inform efforts aimed at advancing the development of and accessibility to devices that enable clinical gastroenterological procedures on awake individuals and research on dietary components-host interactions and gut microbiota ecology in discrete gastrointestinal (GI) regions, with the focus on advancing host-diet microbial interactions. The information respondents provide will help characterize what technologies are currently available to facilitate the study of discrete regions of the human GI tract as well as identify key priorities and reco...
Source: NIDDK Funding Opportunities - July 25, 2019 Category: Endocrinology Source Type: funding
Mass Spectrometric Assays for the Reliable and Reproducible Detection of Proteins/Peptides of Importance in Obesity Research (U01 Clinical Trial Not Allowed)
Funding Opportunity RFA-DK-19-001 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing the development of targeted mass spectrometric assays (e.g., Multiple Reaction Monitoring) for proteins and peptides of primary interest to the obesity research community (e.g., Adiponectin, Leptin, Resistin, Neuropeptide Y, Alpha-melanocyte-stimulating hormone, Peptide YY, Glucagon-like peptide 1, Ghrelin, Adrenocorticotropin, Corticotropin-releasing hormone, Gastrin, Cholecystokinin, Secretin, Vasoactive intestinal peptide, gastric-...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 23, 2019 Category: Research Source Type: funding
Mass Spectrometric Assays for the Reliable and Reproducible Detection of Proteins/Peptides of Importance in Obesity Research (U01 Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing the development of targeted mass spectrometric assays (e.g., Multiple Reaction Monitoring) for proteins and peptides of primary interest to the obesity research community (e.g., Adiponectin, Leptin, Resistin, Neuropeptide Y, Alpha-melanocyte-stimulating hormone, Peptide YY, Glucagon-like peptide 1, Ghrelin, Adrenocorticotropin, Corticotropin-releasing hormone, Gastrin, Cholecystokinin, Secretin, Vasoactive intestinal peptide, gastric-inhibitory peptide, gastrin-releasing peptide, motilin, pancreatic polypeptide,RBP...
Source: NIDDK Funding Opportunities - January 23, 2019 Category: Endocrinology Source Type: funding
Notice of Clarification of Eligible Individuals [Program Director(s)/Principal Investigator(s)] for RFA-DK-18-009, Gastrointestinal Mechanisms Contributing to HIV Pathogenesis (R01 Clinical Trial Not Allowed)
Notice NOT-DK-18-018 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 9, 2018 Category: Research Source Type: funding
Gastrointestinal Mechanisms Contributing to HIV Pathogenesis (R01 Clinical Trial Not Allowed)
Funding Opportunity RFA-DK-18-009 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) seeks to bring together investigators with complementary expertise in HIV and in gastrointestinal mucosal pathobiology to dissect fundamental processes within the gastrointestinal tract that impact HIV infection, persistence, and comorbidities. This multidisciplinary approach should lead to comprehensive, in-depth mechanistic analyses and advance progress toward alleviating comorbidities that afflict people living with HIV and toward developing a cure. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - June 11, 2018 Category: Research Source Type: funding
Gastrointestinal Mechanisms Contributing to HIV Pathogenesis (R01 Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) seeks to bring together investigators with complementary expertise in HIV and in gastrointestinal mucosal pathobiology to dissect fundamental processes within the gastrointestinal tract that impact HIV infection, persistence, and comorbidities. This multidisciplinary approach should lead to comprehensive, in-depth mechanistic analyses and advance progress toward alleviating comorbidities that afflict people living with HIV and toward developing a cure.RFA-DK-18-009 (Source: NIDDK Funding Opportunities)
Source: NIDDK Funding Opportunities - June 11, 2018 Category: Endocrinology Source Type: funding
Addressing Health Disparities in NIDDK Diseases (R01 - Clinical Trial Not Allowed)
Funding Opportunity PA-18-412 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites research to understand and mitigate health disparities in the development, diagnosis, and treatment of diseases of high priority to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Research is encouraged in the following high priority diseases: diabetes and other endocrine and metabolic diseases; obesity; nutrition-related disorders; hepatitis C; gallbladder disease; H. Pylori infection; complications of sickle cell disease within the NIDDK mission areas; kidney dise...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 17, 2017 Category: Research Source Type: funding
Addressing Health Disparities in NIDDK Diseases (R01 - Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) invites research to understand and mitigate health disparities in the development, diagnosis, and treatment of diseases of high priority to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Research is encouraged in the following high priority diseases: diabetes and other endocrine and metabolic diseases; obesity; nutrition-related disorders; hepatitis C; gallbladder disease; H. Pylori infection; complications of sickle cell disease within the NIDDK mission areas; kidney diseases; urologic diseases; metabolic, gastrointestinal, hepatic, and renal compl...
Source: NIDDK Funding Opportunities - November 17, 2017 Category: Endocrinology Source Type: funding
Studies of HIV in Digestive Diseases Limited to Gastrointestinal Mucosal Immunology and Liver Diseases (R01- Clinical Trial Optional)
Funding Opportunity RFA-DK-17-038 from the NIH Guide for Grants and Contracts. The goal of this FOA is to support innovative, basic and translational research in two areas, gastrointestinal (GI) mucosal immunology and liver disease. The emphasis for GI mucosal immunology is on elucidation of mechanisms whereby innate and adaptive immunity in the GI tract interacts with HIV infection in the presence or absence of antiretroviral therapy (ART) and contributes to HIV infection, persistence, disruption of GI homeostasis, and pathogenesis. The emphasis for liver disease is on pathophysiologic mechanisms of injury to the liver...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 9, 2017 Category: Research Source Type: funding
Studies of HIV in Digestive Diseases Limited to Gastrointestinal Mucosal Immunology and Liver Diseases (R01- Clinical Trial Optional)
The goal of this FOA is to support innovative, basic and translational research in two areas, gastrointestinal (GI) mucosal immunology and liver disease. The emphasis for GI mucosal immunology is on elucidation of mechanisms whereby innate and adaptive immunity in the GI tract interacts with HIV infection in the presence or absence of antiretroviral therapy (ART) and contributes to HIV infection, persistence, disruption of GI homeostasis, and pathogenesis. The emphasis for liver disease is on pathophysiologic mechanisms of injury to the liver and the biliary system during HIV infection and epidemiological studies of liver ...
Source: NIDDK Funding Opportunities - November 9, 2017 Category: Endocrinology Source Type: funding
Specialized Programs of Research Excellence (SPOREs) in Human Cancers for years 2018, 2019 and 2020 (P50)
Funding Opportunity PAR-18-313 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) invites applications for P50 Research Center Grants for Specialized Programs of Research Excellence (SPOREs). The program will fund P50 SPORE grants to support state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment of an organ-specific cancer or a related group of cancers. For the purpose of this FOA, cancers derived from the same organ system (i.e., a group of organs that perform a common function) are consi...
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 12, 2017 Category: Research Source Type: funding
